약물관련골괴사(Medication-Related Osteonecrosis of the jaw): 2014 update of BRONJ

키워드

참고문헌 (32)

1. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update", J Oral Maxillofac Surg, 67, pp.2~12 (2009)
2. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update", J Oral Maxillofac Surg Oct, 72(10), pp.1938~1956 (2014)
3. Rosen LS, "Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, Phase III, double-blind, placebo-controlled trial", Cancer, 100, pp.2613~ (2004)
4. "Food and Drug Administration"[URL]
5. Delmas PD, "The use of bisphosphonates in the treatment of osteoporosis", Curr Opin Rheumatol, 17, pp.462~ (2005)
6. Papapoulos S, "Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension", J Bone Miner Res, 27, pp.694~ (2012)
7. Fizazi K, "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study", Lancet, 377, pp.813~ (2011)
8. Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~ (2003)
9. Baron R, "Denosumab and bisphosphonates:different mechanisms of action and effects", Bone, 48, pp.677~ (2011)
10. Marx R, "Oral and Intravenous Bisphosphonate Induced Osteonecrosis of the Jaws: History, etiology, prevention, and treatment" (2011), Quintessence Publishing Co
11. Sedghizadeh PP, "Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy", J Oral Maxillofac Surg, 66, pp.767~ (2008)
12. Landesberg R, "Potential pathophysiological mechanisms in osteonecrosis of the jaw", Ann N Y Acad Sci, 1218, pp.62~ (2011)
13. Santini D, "Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients", Clin Cancer Res, 9, pp.2893~ (2003)
14. Landesberg R, "Inhibition of oral mucosal cell wound healing by bisphosphonates", J Oral Maxillofac Surg, 66, pp.839~ (2008)
15. Scagliotti GV, "Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study", J Thorac Oncol, 7, pp.1823~ (2012)
16. Guarneri V, "Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanc-ed breast cancer", Breast Cancer Res Treat, 122, pp.181~ (2010)
17. Malden N, "An epidemiological study of alendronaterelated osteonecrosis of the jaws. A case series from the southeast of Scotland with attention given to case definition and prevalence", J Bone Miner Metab, 30, pp.171~ (2012)
18. Lo JC, "Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68, pp.243~ (2010)
19. Henry DH, "Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma", J Clin Oncol, 29, pp.1125~ (2011)
20. Kunchur R, "Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws", J Oral Maxillofac Surg, 67, pp.1167~ (2009)
21. Yamazaki T, "Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study", Int J Oral Maxillofac Surg, 41, pp.1397~ (2012)
22. Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded activecontrolled phase III trials in cancer patients with bone metastases", Ann Oncol, 23, pp.1341~ (2012)
23. Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27, pp.5356~ (2009)
24. Brown JJ, "Bisphosphonateassociated osteonecrosis of the jaw: does it occur in children?", Clin Endocrinol, 68, pp.863~ (2008)
25. Vandone AM, "Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience", Ann Oncol, 23, pp.193~ (2012)
26. Hellstein JW, "Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs", J Am Dent Assoc, 142, pp.1243~ (2011)
27. Khan AA, "Bisphosphonate associated osteonecrosis of the jaw", J Rheumatol, 36(3), pp.478~ (2009)
28. Damm DD, "Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays", Gen Dent, 61, pp.33~ (2013)
29. "Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws", American Association of Endodontists, 4~ (2010)
30. Eckardt AM, "Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem", Anticancer Res, 31, pp.2313~ (2011)
31. Kademani D, "Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy", Mayo Clin Proc, 81, pp.1100~ (2006)
32. Yamashita J, "Antiresorptives and osteonecrosis of the jaw", J Evid Based Dent Pract, 12, pp.233~ (2012)

관련 논문AI추천